Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maja Krajinovic

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
Pharmacogenomics|July 4, 2008
MTHFD1 gene: role in disease susceptibility and pharmacogeneticsMaja Krajinovic
Pharmacogenomics and Personalized Medicine|May 17, 2017
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseRachid Abaji, Maja Krajinovic
Current Opinion in Pediatrics|January 17, 2007
Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapyMarc Ansari, Maja Krajinovic
Pharmacogenomics|October 8, 2004
Pharmacogenetics of methotrexateMaja Krajinovic, Albert Moghrabi
Expert Opinion on Drug Metabolism & Toxicology|January 23, 2016
Current perspective on pediatric pharmacogenomicsRachid Abaji, Maja Krajinovic
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Pharmacogenetics of asparaginase in acute lymphoblastic leukemiaRachid Abaji, Maja Krajinovic
Pharmacogenomics|February 5, 2008
Pharmacogenomics of acute leukemiaMarc Ansari, Maja Krajinovic
Pharmacogenomics|November 7, 2009
Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Marc Ansari, Maja Krajinovic
Genome Medicine|December 3, 2010
The pharmacogenetics of imanitibStéphanie Dulucq, Maja Krajinovic
Current Genomics|June 2, 2011
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomesBahram S Askari, Maja Krajinovic
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
Pharmacogenomics|July 4, 2008
MTHFD1 gene: role in disease susceptibility and pharmacogeneticsMaja Krajinovic
Pharmacogenomics and Personalized Medicine|May 17, 2017
Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseRachid Abaji, Maja Krajinovic
Current Opinion in Pediatrics|January 17, 2007
Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapyMarc Ansari, Maja Krajinovic
Pharmacogenomics|October 8, 2004
Pharmacogenetics of methotrexateMaja Krajinovic, Albert Moghrabi
Expert Opinion on Drug Metabolism & Toxicology|January 23, 2016
Current perspective on pediatric pharmacogenomicsRachid Abaji, Maja Krajinovic
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Pharmacogenetics of asparaginase in acute lymphoblastic leukemiaRachid Abaji, Maja Krajinovic
Pharmacogenomics|February 5, 2008
Pharmacogenomics of acute leukemiaMarc Ansari, Maja Krajinovic
Pharmacogenomics|November 7, 2009
Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Marc Ansari, Maja Krajinovic
Genome Medicine|December 3, 2010
The pharmacogenetics of imanitibStéphanie Dulucq, Maja Krajinovic
Current Genomics|June 2, 2011
Dihydrofolate reductase gene variations in susceptibility to disease and treatment outcomesBahram S Askari, Maja Krajinovic
Pageof 17